Last reviewed · How we verify
Essential thrombocythemia
Approved treatments
- Agrylin · Takeda
Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.
Pipeline
- HYDROXYUREA — Phase 3
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Essential thrombocythemia patent landscape — cliff calendar, originator estates, attackable patents
- Essential thrombocythemia treatment landscape brief
- Essential thrombocythemia treatment updates RSS
Frequently asked questions about Essential thrombocythemia
What drugs treat Essential thrombocythemia?
Tracked treatments include Agrylin.
What is the treatment for Essential thrombocythemia?
Standard treatment for Essential thrombocythemia includes Agrylin. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Essential thrombocythemia?
1 pipeline drugs tracked. Top candidates: HYDROXYUREA.
Related
- Treatment landscape: Essential thrombocythemia patent cliff · Essential thrombocythemia CI report
- Treatment: Agrylin · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing